Holen Sie sich die Stockscreener-App
13.00
0.23%
-0.19
Schlusskurs vom Vortag:
$13.19
Offen:
$13.07
24-Stunden-Volumen:
51,892
Relative Volume:
0.02
Marktkapitalisierung:
$1.66B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-44.83
EPS:
-0.29
Netto-Cashflow:
$-31.85M
1W Leistung:
+15.34%
1M Leistung:
+12.86%
6M Leistung:
+102.15%
1J Leistung:
+356.94%
1-Tages-Spanne:
$12.84
$13.26
1-Wochen-Bereich:
$11.21
$13.78
52-Wochen-Spanne:
$2.36
$13.78
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie TRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
12.98 | 1.69B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.04 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.30 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.71 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
895.21 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.28 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Jefferies Financial Group Inc. Makes New Investment in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Tejara Capital Ltd Purchases 146,879 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Sets New 52-Week HighStill a Buy? - MarketBeat
Stocks of Trevi Therapeutics Inc (TRVI) are poised to climb above their peers - Setenews
Trevi Therapeutics stock hits all-time high at 12.31 USD - Investing.com
AXQ Capital LP Invests $227,000 in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN
The Bull Case For Trevi Therapeutics (TRVI) Could Change Following Narrowed Losses and New Shelf Registration - simplywall.st
Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight - GlobeNewswire Inc.
MAI Capital Management Sells 537,497 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Enhances Neurology-Focused Drug Programs - Kalkine Media
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts - MarketBeat
Leerink Partnrs Has Bullish Outlook for TRVI FY2025 Earnings - MarketBeat
B. Riley Increases Earnings Estimates for Trevi Therapeutics - MarketBeat
Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate - MSN
Leerink Partners Maintains Trevi Therapeutics (TRVI) Outperform Recommendation - Nasdaq
TRVI's Price Target Raised by Leerink Partners to $16.00, Mainta - GuruFocus
What is B. Riley's Forecast for TRVI Q1 Earnings? - MarketBeat
Can Trevi Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Fed Impact & Stock Portfolio Risk Management - newser.com
Analyzing drawdowns of Trevi Therapeutics Inc. with statistical toolsBreakout Watch & Verified High Yield Trade Plans - newser.com
How resilient is Trevi Therapeutics Inc. stock in market downturns2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Leerink Partners raises Trevi Therapeutics stock price target to $16 on Haduvio outlook By Investing.com - Investing.com South Africa
Is now a turning point for Trevi Therapeutics Inc.Insider Selling & Weekly Top Gainers Trade List - newser.com
Technical signs of recovery in Trevi Therapeutics Inc.Trade Risk Report & Fast Exit/Entry Strategy Plans - newser.com
Is Trevi Therapeutics Inc. stock a buy for dividend growthTrade Performance Summary & Safe Entry Zone Identification - newser.com
Leerink Partners raises Trevi Therapeutics stock price target to $16 on Haduvio outlook - Investing.com Canada
Should I hold or sell Trevi Therapeutics Inc. stock in 2025CEO Change & Consistent Profit Trade Alerts - newser.com
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk (NASDAQ:TRVI) - Seeking Alpha
Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at D. Boral Capital - MarketBeat
Trevi stock rockets on Haduvio study update - MSN
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Strong Earnings - MarketBeat
Momentum divergence signals in Trevi Therapeutics Inc. chartMarket Sentiment Summary & Reliable Entry Point Alerts - newser.com
What MACD signals say about Trevi Therapeutics Inc.July 2025 WrapUp & Entry Point Strategy Guides - newser.com
Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension - Yahoo Finance
How Trevi Therapeutics’ (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations - Yahoo Finance
Oppenheimer Maintains Trevi Therapeutics (TRVI) Outperform Recommendation - Nasdaq
Trevi Therapeutics (NASDAQ:TRVI) Posts Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Ca - GuruFocus
Cantor Fitzgerald reiterates Overweight rating on Trevi Therapeutics stock By Investing.com - Investing.com Canada
Trevi Therapeutics Wins Analyst Praise As Losses Narrow And Cash Stays Strong - Finimize
Oppenheimer Raises Price Target for Trevi Therapeutics (TRVI) to $24 | TRVI Stock News - GuruFocus
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):